EX-32.1 8 ck0002035832-ex32_1.htm EX-32.1

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Aktis Oncology, Inc. (the “Company”) for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1.
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 30, 2026 |  | By: | /s/ Matthew Roden
|  |  | Matthew Roden, PhD
|  |  | Chief Executive Officer (Principal Executive Officer)

Date: March 30, 2026 |  | By: | /s/ Kyle D. Kuvalanka
|  |  | Kyle D. Kuvalanka
|  |  | Chief Financial Officer (Principal Financial and Accounting Officer)

1.